Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
Silverman, Lewis R., Greenberg, Peter, Raza, Azra, Olnes, Matthew J., Holland, James F., Reddy, Premkumar, Maniar, Manoj, Wilhelm, FrancoisVolume:
33
Language:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.2137
Date:
June, 2015
File:
PDF, 1.03 MB
english, 2015